Here, we evaluated whether all known PN-GlyRS variants cause disease through tRNAGly sequestration, or alternatively, whether a subset of these mutations may trigger peripheral neuropathy through a dominant negative effect on GlyRS aminoacylation activity. The gene discussed is GARS1; the disease is peripheral neuropathy.